Monoclonal Antibodies for Cancer Immunotherapy

Science Communicator Platform

Share By

Monoclonal Antibodies for Cancer Immunotherapy Publisher

Zarnani AH^{1, 2} ; Jafari D^{3, 4} ; Bozorgmehr M² ; Shabani M⁵ ; Barzegaryarmohammadi L⁵ ; Ghaemimanesh F⁵ ; Jedditehrani M⁵

Source: Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition Published:2020

Abstract

Over the past few decades, monoclonal antibodies (mAbs), as potent antitumor tools, have remarkably advanced the cancer therapy, because of their target specificity as well as little off-target effects in comparison to most small molecule drugs. The use of antibody engineering methods has made it possible for investigators to develop antibody structures with improved efficacy for application in clinical practice. The development of efficacious therapeutic mAbs entails gaining in-depth knowledge about factors including antibody structure and function, the properties of an ideal tumor antigen, the advantages of employing combinational therapies, and the limitations of antibody-based modalities. This chapter concentrates on mAbs as versatile platforms for cancer immunotherapy. © Springer Nature Switzerland AG 2015, 2021. All rights reserved.

Related Docs

View other Related Docs

1. A Review on Targeting Tumor Microenvironment: The Main Paradigm Shift in the Mab-Based Immunotherapy of Solid Tumors, International Journal of Biological Macromolecules (2022)

2. Bevacizumab Antibody Affinity Maturation to Improve Ovarian Cancer Immunotherapy: In Silico Approach, International Journal of Peptide Research and Therapeutics (2019)

3. An Overview on Display Systems (Phage, Bacterial, and Yeast Display) for Production of Anticancer Antibodies; Advantages and Disadvantages, International Journal of Biological Macromolecules (2022)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (5)

Fazel Shokri (2)

Other Related Docs

4. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)

5. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)

6. Adcs, As Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies, Current Drug Delivery (2020)

7. Receptor Tyrosine Kinase-Like Orphan Receptor 1: A Novel Target for Cancer Immunotherapy, Expert Opinion on Therapeutic Targets (2015)

8. Advances in Phage Display Technology for Drug Discovery, Expert Opinion on Drug Discovery (2015)

9. The Use of Nanoparticles As a Promising Therapeutic Approach in Cancer Immunotherapy, Artificial Cells# Nanomedicine and Biotechnology (2016)

10. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review, Current Cancer Therapy Reviews (2024)

11. A Concise Review on Cancer Treatment Methods and Delivery Systems, Journal of Drug Delivery Science and Technology (2019)

12. Mechanisms of Tumor Cell Resistance to the Current Targeted-Therapy Agents, Tumor Biology (2016)

13. Targets for Improving Tumor Response to Radiotherapy, International Immunopharmacology (2019)

14. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)

15. Combination Therapy of Macromolecules and Small Molecules: Approaches, Advantages, and Limitations, Nanostructures for Cancer Therapy (2017)

16. Personalized Medicine in Breast Cancer: Pharmacogenomics Approaches, Pharmacogenomics and Personalized Medicine (2019)

17. Polyclonal Antibody Against Different Extracellular Subdomains of Her2 Induces Tumor Growth Inhibition in Vitro, Iranian Journal of Immunology (2017)

18. Cancer Imaging With Radiolabeled Monoclonal Antibodies, Cancer Immunology: A Translational Medicine Context# Second Edition (2020)

19. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)

20. Antibody-Drug Conjugates: Possibilities and Challenges, Avicenna Journal of Medical Biotechnology (2019)

Style	Citing Format
MLA	Zarnani AH, et al.. "Monoclonal Antibodies for Cancer Immunotherapy." Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition, vol. , no. , 2020, pp. 273-312.
APA	Zarnani AH, Jafari D, Bozorgmehr M, Shabani M, Barzegaryarmohammadi L, Ghaemimanesh F, Jedditehrani M (2020). Monoclonal Antibodies for Cancer Immunotherapy. Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition, (), 273-312.
Chicago	Zarnani AH, Jafari D, Bozorgmehr M, Shabani M, Barzegaryarmohammadi L, Ghaemimanesh F, Jedditehrani M. "Monoclonal Antibodies for Cancer Immunotherapy." Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition , no. (2020): 273-312.
Harvard	Zarnani AH et al. (2020) 'Monoclonal Antibodies for Cancer Immunotherapy', Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition, (), pp. 273-312.
Vancouver	Zarnani AH, Jafari D, Bozorgmehr M, Shabani M, Barzegaryarmohammadi L, Ghaemimanesh F, et al.. Monoclonal Antibodies for Cancer Immunotherapy. Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition. 2020;():273-312.
BibTex	@article{ author = {Zarnani AH and Jafari D and Bozorgmehr M and Shabani M and Barzegaryarmohammadi L and Ghaemimanesh F and Jedditehrani M}, title = {Monoclonal Antibodies for Cancer Immunotherapy}, journal = {Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition}, volume = {}, number = {}, pages = {273-312}, year = {2020} }
RIS	TY - JOUR AU - Zarnani AH AU - Jafari D AU - Bozorgmehr M AU - Shabani M AU - Barzegaryarmohammadi L AU - Ghaemimanesh F AU - Jedditehrani M TI - Monoclonal Antibodies for Cancer Immunotherapy JO - Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition VL - IS - SP - 273 EP - 312 PY - 2020 ER -

Science Communicator Platform

Authors

Abstract